102,865 Danaher Corporation $DHR Shares Bought by Nan Fung Trinity HK Ltd.

Key Points

• Nan Fung Trinity HK Ltd. increased its Danaher stake by 150.5%, buying 102,865 shares to reach 171,200 shares valued at about $37.9 million at quarter-end.
• Institutional investors own 79.05% of Danaher, while two company executives disclosed stock sales during the period.
• Analysts rate Danaher a “Moderate Buy,” with a consensus price target of $242.91. In its latest quarter, the company beat earnings estimates with $2.11 per share, while revenue rose 8.3% year over year to $6.55 billion.

Nan Fung Trinity HK Ltd. raised its position in Danaher Corporation (NYSE:DHR - Free Report) by 150.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 171,200 shares of the conglomerate's stock after purchasing an additional 102,865 shares during the quarter. Danaher comprises 3.6% of Nan Fung Trinity HK Ltd.'s investment portfolio, making the stock its 8th biggest position. Nan Fung Trinity HK Ltd.'s holdings in Danaher were worth $37,929,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Danaher during the 2nd quarter worth approximately $10,492,520,000. Wellington Management Group LLP raised its position in shares of Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock valued at $3,108,031,000 after buying an additional 1,542,310 shares during the period. Jupiter Topco LLC acquired a new position in Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher in the second quarter valued at approximately $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher in the second quarter valued at approximately $993,846,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insiders Place Their Bets

In other news, CAO Christopher Bouda sold 7,598 shares of Danaher stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the sale, the chief accounting officer directly owned 9,107 shares of the company's stock, valued at approximately $2,136,137.92. The trade was a 45.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregory M. Milosevich sold 2,100 shares of the business's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at $5,158,277.54. This represents a 8.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings upgraded Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 16th. DZ Bank lowered Danaher from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 27th. Royal Bank Of Canada increased their price target on Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a report on Monday, October 5th. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Monday, October 26th. Finally, Morgan Stanley raised their price objective on Danaher from $220.00 to $240.00 and gave the stock an "overweight" rating in a research report on Monday, October 12th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $242.91.

Danaher Stock Performance

Shares of DHR stock opened at $232.08 on Friday. The firm's 50 day moving average price is $222.11 and its 200-day moving average price is $201.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The firm has a market cap of $163.28 billion, a P/E ratio of 37.98, a P/E/G ratio of 2.95 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping analysts' consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The firm had revenue of $6.55 billion during the quarter, compared to analysts' expectations of $6.56 billion. During the same quarter last year, the company posted $1.89 EPS. The firm's quarterly revenue was up 8.3% on a year-over-year basis. As a group, equities research analysts predict that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Wednesday, September 30th. Danaher's dividend payout ratio is 26.19%.

Danaher Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company's businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.